Results 51 to 60 of about 5,411,820 (260)

Secondary Progression is Not the Only Explanation

Acta Médica Portuguesa, 2014
Multiple sclerosis is an inflammatory demyelinating disorder of the central nervous system. Its presentation is variable and its course and prognosis are unpredictable.
Filipe Palavra, Carmen Tur, Mar Tintoré, Àlex Rovira, Xavier Montalban   +4 more
doaj   +1 more source

Plasma Neurofilament Heavy Chain Levels Correlate to Markers of Late Stage Disease Progression and Treatment Response in SOD1(G93A) Mice that Model ALS [PDF]

, 2012
Background: Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disorder characterised by progressive degeneration of motor neurons leading to death, typically within 3–5 years of symptom onset. The diagnosis of ALS is largely reliant
Greensmith Linda, Dick, J., Lu, C.H., Malaspina, A., Kalmar, B., Greensmith, L., Dick, J, Petzold, A.F.S., Petzold, A, Linda Greensmith, Malaspina Andrea, Petzold Axel, Greensmith, L, Kalmar Bernadett, Kalmar, B, Dick James, Lu Ching-Hua, Lu, CH, Bernadett Kalmar, James Dick, Ching-Hua Lu, Lu, C-H, Andrea Malaspina, Malaspina, A, Axel Petzold   +24 more
core   +3 more sources

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009?

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019
Background Disease-modifying therapies benefit individuals with relapsing forms of multiple sclerosis, but their utility remains unclear for those without relapses.
Sarah L Minden, R Philip Kinkel, Helene T Machado, Jonathan S Levin, Meredith B Rosenthal, Lisa I Iezzoni   +5 more
doaj   +1 more source

Changes in retinal structures as markers of multiple sclerosis progression

Неврология, нейропсихиатрия, психосоматика, 2021
The involvement of the visual pathway in multiple sclerosis (MS) pathology determines the importance of studying the structures of the retina for earlier diagnosis and monitoring the severity of the neurodegeneration.
M. O. Poplyak, A. G. Trufanov, A. V. Temniy, D. S. Maltsev, O. B. Chakchir, A. V. Mikheev, D. I. Skulyabin, G. N. Bisaga, I. V. Litvinenko, M. M. Odinak   +9 more
doaj   +1 more source

Predicting the On-Study Relapse Rate for Multiple Sclerosis Patients in Clinical Trials [PDF]

, 2005
Background: The annual relapse rate has been commonly used as a primary efficacy endpoint in phase III multiple sclerosis (MS) clinical trials. The aim of this study was to determine the relative contribution of different possible prognostic factors ...
Chang, C., Polman, Chris, Kappos, L., Polman, C., Held, U., Heigenhauser, L., Shang, C., Heigenhauser, Ludwig, Kappos, Ludwig   +8 more
core   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis

Неврология, нейропсихиатрия, психосоматика, 2019
The paper presents a detailed algorithm for the treatment and follow-up of patients with recurrent multiple sclerosis and primary progressive multiple sclerosis in the use of ocrelizumab.
A. N. Boyko, M. V. Davydovskaya, N. V. Khachanova, M. N. Zakharova, N. N. Spirin, E. V. Popova, V. M. Alifirova, Ya. V. Vlasov, S. A. Sivertseva, F. A. Khabirov, M. V. Shumilina, E. P. Evdoshenko   +11 more
doaj   +1 more source

Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level

Aging and Cancer, EarlyView.
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley   +1 more source

Diagnosis and Management of Progressive Multiple Sclerosis

Biomedicines, 2019
Multiple sclerosis is a chronic autoimmune disease of the central nervous system that results in varying degrees of disability. Progressive multiple sclerosis, characterized by a steady increase in neurological disability independently of relapses, can ...
Gabrielle Macaron, Daniel Ontaneda
doaj   +1 more source